Search

Displaying results 731 - 740 of 10000 in total
  1. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials … [A214310] It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being

  2. Drug

    Lenvatinib

    go.drugbank.com/drugs/DB09078
    ApprovedInvestigational

    These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as … Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth

  3. Drug

    Emtricitabine

    go.drugbank.com/drugs/DB00879
    ApprovedInvestigational

    in high risk adolescents and adults. … [L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019]

    Mixtures: EMTRICITABINA E TENOFOVIR DISOPROXIL EG, EMTRICITABINA E TENOFOVIR DISOPROXIL EGCategories: Antivirals used in combination for the treatment of HIV infections
  4. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    The cell line used to manufacture Thrombin Alfa has been tested and shown to be free of known infectious agents. … Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line.

  5. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.

  6. Drug

    Aripiprazole

    go.drugbank.com/drugs/DB01238
    ApprovedInvestigational

    [L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.[L6136] … [L45859] It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania.

    Products: ARIPIPRAZOLO EG
  7. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    [A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients … The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost].

    Categories: Receptors, Prostaglandin E, EP2 Subtype, agonistsSynonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinate
  8. Drug

    Soybean oil

    go.drugbank.com/drugs/DB09422
    ApprovedInvestigational

    It is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use.

    Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 MLProducts: LIPOFUNDIN 20 %N, LIPOFUNDIN 10 %N
  9. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    alternative first-line therapies for that disorder [FDA Label]. … Infliximab is produced by a recombinant cell line cultured by continuous perfusion.

    Products: INFLECTRA 100MG PLV F E KO, REMICADE 100MG PULV F E KO
  10. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.

    Synonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamide